Loading...

VSTM VERASTEM INC Expansion Plans 8-K Filing

VRST

VSTM

VERASTEM INC

(VSTM)

2025 8-K

Corporate Update

Financial Results Update

Corporate Presentation Update

Trial Discontinuation

Management Change

Stock Offering Announcement

Financial Results

Clinical Trial Update

Efficacy Update

Corporate Update

Safety Data Release

Investor Meetings

Market Expansion

New Product Launches

Equity Offerings

Corporate Update

Collaboration Update

Management Change

Funding Agreement

Clinical Trial Update

Underwriting Agreement

NDA Submission for Avutomet...

Corporate Presentation

Annual Meeting Results

Regulation FD Disclosure

Stockholder Vote on Option ...

Amendment to Loan Agreement

CFO Appointment

Appointment of CEO

Underwriting Agreement

Reverse Stock Split

Press Release Update

Annual Meeting of Stockholders

Loan Agreement with Oxford ...

Regulation FD Disclosure

Financial Condition

Private Placement

Press Release and Private P...

External Links:

On June 2, 2025, Verastem, Inc. announced promising results from a Phase 1 study of its drug VS-7375 for treating advanced KRAS G12D mutant solid tumors, showing a 52% overall response rate in pancreatic cancer and a 42% rate in non-small cell lung cancer with no significant toxicities.

AI Assistant

VERASTEM INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.